Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Summary

This is a prospective, open-label, multi-center, single-arm clinical trial

Timeline

Start

2021-07-09

Primary completion

2024-06-15

Completion

2024-07-15

Publications

• Li H, Chen K, Gong L, Qin J, Jin Y, Zhou R, Huang Z, Xu Y, Xu X, He J, Zhu J, Yu S, Lu H, Xu Y, Yu X, Han G, Chen J, Tan W, Lou G, Ren B, Chen X, Zhang D, Wang W, Shi X, Xie F, Zhao J, Han N, Li B, Fan Y. High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 Aug 1;11(8):900-908. doi: 10.1001/jamaoncol.2025.1779.

Drugs

Indications